Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy

WB starts Zura Bio at OP; sum-of-the-parts NPV estimate $13.90 - BioTuesdays

William Blair launched coverage of Zura Bio (NASDAQ:ZURA) with an “outperform” rating and sum-of-the-parts NPV estimate of $13.90. The stock closed at $5.08 on July 7. Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. The company’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goa…

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy

On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead …